Prevention strategies will be developed to take advantage of the metabolic and behavioral risk factors for NIDDM which have been identified in research with the Pima Indians and elsewhere. Obesity, impaired glucose tolerance, hyperinsulinemia, physical inactivity, and high fat diet have been implicated as risk factors for NIDDM. Since these factors are potentially reversible with behavioral and pharmacologic therapy, strategies for prevention will be developed and tested. A feasibility study of diet and exercise treatment has been conducted among overweight Pima Indians with normal glucose tolerance. Knowledge and experience gained from this pilot study will be used in planning and implementing the national, multicenter clinical trial in prevention of NIDDM, in which the investigators will participate.
| Knowler, William C (2006) Optimal diet for glycemia and lipids. Nestle Nutr Workshop Ser Clin Perform Programme 11:97-102; discussion 102-5 |
| Florez, Jose C; Jablonski, Kathleen A; Bayley, Nick et al. (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355:241-50 |
| Knowler, William C; Hamman, Richard F; Edelstein, Sharon L et al. (2005) Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54:1150-6 |
| Rubin, Richard R; Knowler, William C; Ma, Yong et al. (2005) Depression symptoms and antidepressant medicine use in Diabetes Prevention Program participants. Diabetes Care 28:830-7 |
| Kitabchi, Abbas E; Temprosa, Marinella; Knowler, William C et al. (2005) Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 54:2404-14 |
| Molitch, Mark E; Fujimoto, Wilfred; Hamman, Richard F et al. (2003) The diabetes prevention program and its global implications. J Am Soc Nephrol 14:S103-7 |
| Knowler, William C; Barrett-Connor, Elizabeth; Fowler, Sarah E et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403 |
